NDAINTRAVENOUSINJECTABLE
Approved
Jul 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE (nicardipine hydrochloride) by Hikma is concentrations. First approved in 2008.
Drug data last refreshed 18h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Nicardipine hydrochloride in 0.9% sodium chloride is an intravenous calcium channel blocker formulation used for acute hypertension management in hospital settings. It works by selectively inhibiting calcium ion influx into vascular smooth muscle cells, producing vasodilation with minimal cardiac depression. The drug is administered parenterally for rapid blood pressure control in acute care environments.
LOE Approaching
Product faces moderate competitive pressure (30/100) and approaching loss of exclusivity, signaling potential team contraction or transition planning for commercial organizations.
Mechanism of Action
concentrations. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. The effects of nicardipine are more selective to vascular smooth muscle than cardiac muscle. In animal…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on nicardipine offers experience in acute-care institutional marketing, hospital formulary management, and defensive commercial strategy in a mature market. This role emphasizes payer negotiations, clinical evidence communication, and competitive positioning rather than growth-phase launch activities.
Hospital/Institutional Sales Representative
Worked on NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.